Does Medicare Cover Ozempic or Wegovy for Weight Loss?

Medicare coverage for GLP-1 weight loss medications has been one of the more closely watched policy questions in healthcare over the past two years, and the answer has been shifting. The short version: Medicare has historically excluded weight loss drugs from Part D coverage, but that’s beginning to change in narrow circumstances. If you’re on Medicare and hoping to access Wegovy or Ozempic for weight loss, here’s exactly where things stand and what your options are.

The Historical Exclusion and Why It Exists

Medicare Part D, the prescription drug benefit, was established under legislation that explicitly excluded coverage for weight loss medications. This wasn’t an oversight. It was a deliberate policy decision reflecting the view, prevalent at the time, that obesity was a lifestyle issue rather than a medical condition requiring drug treatment.

That framing has shifted significantly in the years since. Obesity is now recognized by the American Medical Association and most major medical organizations as a chronic disease with complex biological drivers. The GLP-1 medications that have emerged over the past decade are among the most effective pharmacological treatments ever developed for it. But the statutory exclusion in Medicare Part D has been slow to catch up with that clinical reality.

The result is that for most Medicare beneficiaries, coverage for Wegovy or Ozempic specifically for weight loss remains limited or unavailable depending on their plan and diagnosis status.

Where Coverage Currently Exists for Medicare Patients

There are two pathways where Medicare coverage for GLP-1 medications becomes available, and understanding both is important.

Type 2 diabetes indication. Ozempic is FDA-approved for type 2 diabetes management, and Medicare Part D covers it for that indication. If you have a type 2 diabetes diagnosis and your provider prescribes Ozempic for blood sugar management, Medicare will generally cover it, subject to prior authorization, tier placement, and cost-sharing under your specific Part D plan. The same applies to Mounjaro (tirzepatide) for diabetes.

The catch is that using Ozempic for weight loss when you have diabetes is clinically common, but Medicare’s coverage is tied to the diabetes indication. If your provider documents the prescription for diabetes management and you happen to lose weight as a result, that’s covered. If the documentation frames it as weight loss treatment, coverage becomes more complicated.

Cardiovascular risk reduction. This is where things have genuinely changed. Following the landmark SELECT trial, which demonstrated that semaglutide significantly reduced major cardiovascular events in people with obesity and established cardiovascular disease, the Centers for Medicare and Medicaid Services (CMS) issued guidance allowing Medicare Part D plans to cover Wegovy for cardiovascular risk reduction in patients who meet specific criteria.

Those criteria are meaningful: you need to have established cardiovascular disease, defined as a prior heart attack, stroke, or peripheral arterial disease, along with a BMI of 27 or above. Weight loss alone, without the cardiovascular disease component, does not qualify under this pathway.

If you meet those criteria, coverage depends on whether your specific Part D plan has added Wegovy to its formulary for this indication. Not all plans have done so, and those that have may still require prior authorization. For more on the SELECT trial findings and what they mean for patients, the SELECT trial and what it means for Ozempic patients covers the clinical details.

What Medicare Advantage Plans Cover

Medicare Advantage plans, sometimes called Part C, are administered by private insurers and may have somewhat different formularies than traditional Medicare. Some Medicare Advantage plans have added GLP-1 coverage beyond what traditional Medicare Part D offers, particularly for the cardiovascular risk reduction indication.

If you’re on a Medicare Advantage plan, check your plan’s formulary directly rather than assuming it mirrors traditional Medicare. The insurer administering your plan, whether that’s Humana, UnitedHealthcare, Anthem, or another carrier, sets the specific drug coverage within the bounds CMS allows.

The Legislative Landscape

There has been meaningful congressional interest in expanding Medicare coverage for obesity medications more broadly. The Treat and Reduce Obesity Act, which would remove the statutory exclusion for weight loss drugs from Part D, has been introduced in multiple congressional sessions. As of the time of writing, it has not passed, but the political and policy momentum behind broader coverage has been building.

If this legislation passes, it would represent a significant shift in access for Medicare beneficiaries. In the meantime, coverage remains tied to the diabetes and cardiovascular disease pathways described above for most patients.

Prior Authorization for Medicare GLP-1 Coverage

When Medicare or a Medicare Advantage plan does cover a GLP-1 medication, prior authorization is standard. Your provider will need to document that you meet the relevant clinical criteria, whether that’s a diabetes diagnosis for Ozempic or the cardiovascular disease plus BMI threshold for Wegovy under the SELECT pathway.

The prior authorization process and timelines vary by plan. Your provider’s office typically handles the submission, and having a provider who is familiar with the documentation requirements helps move the process along. If you’re denied, the appeals process is available and worth pursuing with strong clinical documentation.

What Medicare Patients Can Do If Coverage Isn’t Available

If you’re on Medicare and don’t qualify for coverage under the current pathways, or if your specific plan hasn’t added the coverage that CMS has allowed, you’re not without options.

Compounded semaglutide is available at cash pay prices through telehealth providers like TrimRx and represents a substantially more affordable alternative to brand-name Wegovy or Ozempic without insurance coverage. It’s not covered by Medicare, but the out-of-pocket cost is significantly lower than paying full price for a brand-name medication.

Consider this scenario: a 68-year-old Medicare beneficiary who doesn’t have an established cardiovascular disease diagnosis wants to lose 35 pounds to reduce her blood pressure and joint pain. She doesn’t qualify under the current Medicare pathways for Wegovy coverage. Through a telehealth provider, she accesses compounded semaglutide at a manageable monthly cost, works with a licensed provider throughout her treatment, and achieves her goal over eight months.

That’s a realistic path for Medicare patients who fall outside the current coverage criteria. How to get GLP-1 medications without insurance covers the full range of access options in more detail.

For patients who want to understand what compounded semaglutide actually is and how it compares to the brand-name version, compounded semaglutide vs Wegovy walks through the key differences clearly.

Checking Your Specific Medicare Coverage

To find out exactly what your plan covers, log into medicare.gov and use the formulary lookup tool, or log into your Medicare Advantage plan’s member portal if you’re on a Part C plan. Search for semaglutide and tirzepatide by generic name and review the coverage details, prior authorization requirements, and cost-sharing information.

You can also call 1-800-MEDICARE directly or your plan’s member services line to ask specifically whether Wegovy is covered for cardiovascular risk reduction under your plan and what documentation your provider would need to submit.

If coverage isn’t available and you want to explore affordable alternatives, start your assessment at TrimRx to find out whether you’re a candidate for compounded GLP-1 treatment.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.